Form 13-F position report

LA JOLLA PHARMACEUTICAL CO

Reported by TANG KEVIN C

LJPC CUSIP 503459604 Manager CIK 0001178579

Reported 240,000 shares, unchanged from the prior quarter.

Reported value 6.9%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 80.13% This manager · Q1 2020
Shares 240,000 Quarter-end amount reported
Reported value $1,008,000 Fair value at quarter end
Consecutive quarters held 5 Through Q1 2020

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2019-03-31 1543000
2019-06-30 2220000
2019-09-30 2112000
2019-12-31 943000
2020-03-31 1008000
2020-06-30 1022000
2020-09-30 967000
2020-12-31 931000
2021-03-31 1018000
2021-06-30 1027000
2021-09-30 958000
2021-12-31 1116000
2022-03-31 1025000
2022-06-30 766000
2022-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for LA JOLLA PHARMACEUTICAL CO held by TANG KEVIN C.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2022 Reduced 0 -240,000 (-100.0%) 0 $0 2022-11-14
Q2 2022 Unchanged 240,000 0 (0.0%) 99.74% $766,000 2022-08-15
Q1 2022 Unchanged 240,000 0 (0.0%) 99.61% $1,025,000 2022-05-16
Q4 2021 Unchanged 240,000 0 (0.0%) 99.38% $1,116,000 2022-02-14
Q3 2021 Unchanged 240,000 0 (0.0%) 99.17% $958,000 2021-11-15
Q2 2021 Unchanged 240,000 0 (0.0%) 95.09% $1,027,000 2021-08-16
Q1 2021 Unchanged 240,000 0 (0.0%) 94.79% $1,018,000 2021-05-17
Q4 2020 Unchanged 240,000 0 (0.0%) 92.73% $931,000 2021-02-16
Q3 2020 Unchanged 240,000 0 (0.0%) 78.24% $967,000 2020-11-16
Q2 2020 Unchanged 240,000 0 (0.0%) 79.29% $1,022,000 2020-08-14
Q1 2020 Unchanged 240,000 0 (0.0%) 80.13% $1,008,000 2020-05-15
Q4 2019 Unchanged 240,000 0 (0.0%) 11.17% $943,000 2020-02-14
Q3 2019 Unchanged 240,000 0 (0.0%) 75.03% $2,112,000 2019-11-14
Q2 2019 Unchanged 240,000 0 (0.0%) 75.87% $2,220,000 2019-08-14
Q1 2019 New 240,000 +240,000 (0.0%) 61.84% $1,543,000 2019-05-15

Who else reported the position

82 managers reported LA JOLLA PHARMACEUTICAL CO for Q1 2020.

Managers reporting LA JOLLA PHARMACEUTICAL CO in Q1 2020.
Manager Activity Shares Change % of reported 13F Reported value Tenure
TANG CAPITAL MANAGEMENT LLC Added 8,080,345 +3,141,452 4.77% $33,937,000 25 qtrs
RTW INVESTMENTS LP Added 2,354,734 +66,743 0.43% $9,890,000 22 qtrs
BlackRock Inc Reduced 1,551,354 -22,982 < 0.01% $6,516,000 20 qtrs
FMR LLC Reduced 1,254,989 -29 < 0.01% $5,271,000 25 qtrs
VANGUARD GROUP INC Reduced 1,015,886 -11,458 < 0.01% $4,267,000 23 qtrs
Boxer Capital LLC Added 890,700 +115,700 0.25% $3,741,000 4 qtrs
MORGAN STANLEY Added 637,920 +256,046 < 0.01% $2,679,000 25 qtrs
STATE STREET CORPORATION Reduced 409,448 -19,610 < 0.01% $1,720,000 20 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 315,278 -34,983 < 0.01% $1,324,000 25 qtrs
NORTHERN TRUST CORPORATION Added 298,285 +222 < 0.01% $1,252,000 23 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2020
Filed
May 15, 2020
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
240,000
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.